Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Novartis AG is a global pharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative medicines. The company operates primarily within the pharmaceuticals and biotechnology industries, with a strategic emphasis on patented, science-driven therapies for serious diseases. Novartis’s core revenue is generated from prescription medicines, particularly in areas such as oncology, immunology, neuroscience, cardiovascular, renal, and metabolic diseases.
The company serves healthcare systems, hospitals, physicians, and patients across developed and emerging markets. Its competitive positioning is built on a strong pipeline of innovative therapies, global scale, and deep scientific capabilities in drug discovery and development. Novartis traces its roots to the mid-19th century in Switzerland, evolving through mergers and restructuring into a modern, innovation-focused medicines company. In recent years, it has simplified its structure, including the 2023 spin-off of its generics business, Sandoz Group AG, to focus exclusively on innovative pharmaceuticals.
Business Operations
Novartis operates primarily through a single reporting segment, Innovative Medicines, which encompasses all marketed products and research and development activities. Revenue is generated through the sale of patented prescription drugs, including leading therapies such as Entresto, Cosentyx, Kesimpta, Kisqali, and Leqvio. The company maintains extensive in-house capabilities across research, clinical development, regulatory affairs, manufacturing, and global commercialization.
Operations are supported by a global network of research centers, manufacturing sites, and commercial organizations across North America, Europe, and Asia-Pacific. Novartis controls advanced platforms in small molecules, biologics, gene and cell therapies, and radioligand therapies. It collaborates with biotechnology firms, academic institutions, and technology partners, while also operating through wholly owned subsidiaries in key markets to manage local regulatory, manufacturing, and commercial activities.
Strategic Position & Investments
Novartis’s strategy centers on becoming a focused “pure-play” innovative medicines company, prioritizing high-growth therapeutic areas and scalable technology platforms. Growth initiatives include advancing its late-stage pipeline, expanding radioligand therapy capabilities, and increasing investment in data science and artificial intelligence to enhance drug development productivity. The company consistently allocates significant capital to internal research and development, alongside targeted external innovation.
Major investments and acquisitions have supported this strategy, including the integration of Advanced Accelerator Applications and Endocyte to strengthen its radioligand therapy franchise. Novartis has also divested non-core assets, such as the separation of Sandoz Group AG, to sharpen strategic focus. Emerging areas of involvement include gene therapies, xRNA-based medicines, and cardiovascular and renal therapies with blockbuster potential.
Geographic Footprint
Novartis is headquartered in Basel, Switzerland, and operates in more than 100 countries worldwide. Its largest markets include North America—particularly the United States—which represents the single largest source of revenue, followed by Europe and Asia-Pacific. The company maintains significant market presence across Japan, China, and major European Union countries.
Manufacturing, research, and development activities are distributed globally, with major sites in Switzerland, the United States, Germany, Ireland, Singapore, and China. This global footprint supports both local market access and international supply chains, enabling Novartis to serve diverse healthcare systems and regulatory environments while maintaining global operational scale.
Leadership & Governance
Novartis is led by an executive team focused on innovation, operational excellence, and long-term value creation for patients and shareholders. The leadership philosophy emphasizes scientific rigor, ethical governance, and disciplined capital allocation aligned with strategic priorities.
Key executives include:
- Vasant Narasimhan – Chief Executive Officer
- Harry Kirsch – Chief Financial Officer
- Marie-France Tschudin – President, Innovative Medicines U.S.
- Shreeram Aradhye – President, Development and Chief Medical Officer
- Ronny Gal – Chief Strategy & Growth Officer
- Lutz Hegemann – President, Global Health and Sustainability
The company is governed by a Board of Directors that oversees strategy, risk management, and compliance, consistent with Swiss corporate governance standards and public company reporting requirements.